Nebenwirkungen · Tecentriq
Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1 200 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 23
HOS-135681 · Präparat HOS-097762
Hepatitis occurred in 1.7% (88/5 039) of patients who received atezolizumab monotherapy. Of the 88 patients, three experienced fatal events. The median time to onset was 1.4 months (range: 0 days to 26.3 months). The median duration was 1 month (range: 0 day to 52.1+ months; + denotes a censored value). Hepatitis led to discontinuation of atezolizumab in 46 (0.9%) patients. Hepatitis requiring the use of corticosteroids occurred in 2.6% (130/5 039) of patients receiving atezolizumab monotherapy.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T14:01:00Z · SHA-256 18e3f8552b876a534d8511fca3cff4c3dca0b9b65dfd3c4f6e802bbe650c2f98 · Passage 62a3e35891b2d7050f756e6d3f9de7ccbbe53ecfd1374c87d520760e26df5e1d · Zeichen 17648–18148 im Abschnitt